EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Fibroblast Activation Protein Inhibitor Theranostics

Katharina Lückerath, Marija Trajkovic-Arsic, Christine E Mona

PET Clinics · 2023

DOI: 10.1016/j.cpet.2023.02.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift PET Clinics, 2023. Verfasst von Katharina Lückerath und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstrasse 55, 45147…. Hauptthemen laut MEDLINE: Serine Endopeptidases, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 107 Literaturangaben. Gefördert von: University Hospital Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP)-radioligand therapy might be effective in some patients without being curative. FAP-radioligands deliver ionizing radiation directly to FAP+ cancer-associated fibroblasts and, in some cancers, to FAP+ tumor cells; in addition, they indirectly irradiate FAP- cells in tumor tissue via cross-fire and bystander effects. Here, we discuss the potential to improve FAP-radioligand therapy through interfering with DNA damage repair, immunotherapy, and co-targeting cancer-associated fibroblasts. As the molecular and cellular effects of FAP-radioligands on the tumor and its microenvironment have not been investigated yet, we call for future research to close this gap in knowledge, which prevents the development of more effective FAP-radioligand therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Serine EndopeptidasesNeoplasmsHumansPrecision MedicineMembrane ProteinsFibroblastsCell Line, TumorTumor Microenvironment

Stichwörter der Autor:innen

Combination therapyFibroblast activation proteinRadioligandTheranosticsTumor microenvironment

Substanzen

Serine EndopeptidasesMembrane Proteins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany. Electronic address: katharina.lueckerath@uk-essen.de.
  • Division of Solid Tumor Translational Oncology, DKTK and German Cancer Research Center (DKFZ) Partner Side Essen, Hufelandstrasse 15, 45147, Germany; Bridge Institute of Experimental Tumor Therapy, West German Cancer Ce…
  • Ahmanson Translational Theranostic Division, Department of Molecular and Medical Pharmacology, University of California Los Angeles, 650 Charles E Young Drive S, Los Angeles, CA 90095, USA.

Förderung

  • University Hospital Essen

Zitieren

APA

Lückerath, K., Trajkovic-Arsic, M., & Mona, C. E. (2023). Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics. https://doi.org/10.1016/j.cpet.2023.02.006

Vancouver

Lückerath K, Trajkovic-Arsic M, Mona CE. Fibroblast Activation Protein Inhibitor Theranostics. PET Clinics. 2023. doi:10.1016/j.cpet.2023.02.006

BibTeX
@article{Lckerath2023,
  author = {Lückerath, Katharina and Trajkovic-Arsic, Marija and Mona, Christine E},
  title = {Fibroblast Activation Protein Inhibitor Theranostics},
  journal = {PET Clinics},
  year = {2023},
  doi = {10.1016/j.cpet.2023.02.006}
}
Kostenlos starten →